The mammalian target of rapamycin (mTOR) inhibitor, sirolimus, has been used in hyperinsulinemic hypoglycemia which was unresponsive to other medical treatment (3,9). This evidence concerns the gene MTOR and hyperinsulinemic hypoglycemia.